Originally, he thought that it would be the same as China, there are many of them, you must know that in China, although there are so many large pharmaceutical companies that can be called, there are also many small and medium-sized pharmaceutical companies. Pen @ fun @ pavilion wWw. ｂｉｑUｇE。 ｉｎｆｏ。。

Although he has not made specific statistics, according to his estimates, how can there be thousands of them, how can he think that the United States actually counts them, and there are only so many of them?

In this way, it is much more difficult for them to acquire such a business, not to mention that Scott introduced them to an Amgen as soon as he came up!

Although this company is not as famous as Pfizer and Johnson, it is also a top boss in the American pharmaceutical manufacturing industry!

Amgen Pharmaceutical, although its reputation is not as good as that of Pfizer, Johnson, or Novartis, is a large pharmaceutical manufacturing company in the United States, and even in the world.

People's annual turnover is calculated in billions of dollars, and the company's asset scale, based on the current market situation in the United States, is at least about 100 billion dollars.

Such a company, even if Wang Xueming has energy and assets in China, but it is also a fantasy to say that the acquisition of Amgen is a fantasy, not to mention that people are definitely in a super healthy financial state now, and they are not bad at all.

In such a company, if Jin Muchen patronizes the treasures he patronized the Museum of Fine Arts, Boston, and the British Museum, all of them are taken out and bought, and then come to buy them, it is still possible, but if it is the current situation, he and Wang Xueming come to the door and talk about the acquisition, I am afraid that they will not even be able to enter the door of others, and they will be dared to come out by the security guards of others, and it is not impossible for them to be sent to a psychiatric hospital.

If it weren't for Scott, who was sitting across from him, he was a very familiar and reliable person, Jin Muchen really wanted to spray his face with spit all over his face at this time.

What the hell, do you really think Lao Tzu is a stupid old hat from China? actually made such a **** suggestion to Lao Tzu, are you going to play Lao Tzu as a fool?

And Scott looked at the strange look on Jin Muchen's face at this time, of course he knew what he was thinking, so he quickly made his own explanation.

"Dear Mu Chen, don't worry, I'm not talking nonsense to you, in fact, I gave you this advice for a reason."

Scott hurriedly explained to Jin Muchen, and at this time, Jin Muchen also nodded: "Well, I know you're not talking nonsense, so you can tell me about it." ”

"Okay, let me give you a brief introduction to the Amgen company, by the way, you know the Amgen company, right?"

Scott planned to introduce Jin Muchen in an all-round way, and the person he introduced to Jin Muchen, Jin Muchen nodded at this time.

"I've heard the name of Amgen, but how exactly it came to be and what it does, you can give me a fresh look."

Jin Muchen has indeed heard of the name of Amgen Company, but he really doesn't know much about what this company is from, how it has developed, and what it is best at now.

Scott was very happy when he saw that Jin Muchen was half a bucket of water, which showed that Jin Muchen didn't understand the situation, and then nodded and began to speak.

"It's also strange when it comes to the development of this Amgen company, because it was founded by a group of scientists and a group of venture capitalists at the beginning. He was founded in 1981, when President Reagan began to promote the policy of supporting small and medium-sized pharmaceutical manufacturing enterprises in the United States. Three venture capitalists and a group of scientists founded the company in California. At that time, when the company was founded, it had already set its own future development path, that is, not to take the road of traditional pharmaceutical companies, but to rely on the biopharmaceutical model to walk out of their own new development path. ”

Scott really understands this aspect very well, and Jin Muchen nodded frequently when he heard it, this original founding concept of Amgen is really quite novel.

And those scientists and investors are not stupid, knowing that in the field of traditional manufacturing, they must not be able to compare with those giants of traditional medicine manufacturing, so they have taken such an unusual path.

However, since its establishment in 1981, they have been engaged in basic scientific research, and there is no real fist product launch, so they can only rely on continuous fundraising and financing to survive. At that time, they had a miserable life, the $19 million raised from investors was quickly spent, and then they successively engaged in stock financing, but the money was quickly spent, and finally they even mortgaged all the overseas sales rights of their fist products that were about to take shape to Johnson, which was only from Johnson's hands to $19 million, so that they could continue their lives. Their company really ushered in glory from 1986, when they put Abbott Gordon. After Pentax was hired as CEO, the company underwent several reorganizations before it burst into combat effectiveness. In 1989, they launched the world's first recombinant human erythropoietin drug, which is a special drug for those with kidney disease to relieve the pain of hemodialysis and improve the efficacy of hemodialysis. In 1991, they launched recast granulocyte colony-stimulating factor, a special drug for leukopenia caused by cancer chemotherapy, and it was these two drugs that brought the company to its peak. From a pharmaceutical company on the verge of bankruptcy back then, it has become the only one in the pharmaceutical industry in the United States and even the world, although the scale is not large, but it can produce special drugs for a certain disease, and it has also made them famous, so that it has developed into a large pharmaceutical manufacturing enterprise that can almost enter the top ten in the world... ”

Scott can be said to know the development process of this Amgen company well, and after listening to it, Jin Muchen also feels that the development of this company can be called ups and downs, which is indeed interesting.

However, if the company is developing so well now, what does it have to do with itself and Wang Xueming's acquisition?

Scott is a very good person, and when he saw Jin Muchen's face at this time, he immediately knew what he was thinking, so he immediately introduced him.

"It was at that time that Amgen started that Amgen has developed to what it is today, and now this company has become an important leader in the field of pharmaceutical manufacturing in the world, and is a top authority in the fields of human genetic recombination, cancer, neuroscience, and small molecule chemistry. However, the development of this company is not all smooth sailing, for example, in 2000, their company had a fierce conflict at the shareholders' meeting on the direction of development. At that time, it happened to be a node in the development of Amgen, and they were already in the field of new biomedical manufacturing, and there were many projects that had not yet broken through, and some shareholders were very dissatisfied with the company's future profitability. Therefore, when the shareholders' meeting is held, I want to acquire some traditional pharmaceutical manufacturing enterprises, even if I don't engage in research and development, but produce some generic drugs that have passed the patent protection period, then I can make money. As a result, a fierce dispute broke out at the company's shareholders' meeting that year, and there were people on both sides who supported it. ”

When Jin Muchen heard this, he knew that he was about to get to the point, and sure enough, after Scott took a breath, he continued to talk to him.

Later, this controversy lasted for three years, and finally the shareholders who supported entering the field of traditional medicine manufacturing prevailed, so in March 2004, Amgen acquired Dularic in the San Francisco area at a price of $25 per share, a total of $1.3 billion, this company is headquartered in South San Francisco, is a pharmaceutical company specializing in the manufacture of traditional medicine, they also have their own specialty products in the field of traditional medicine, such as special drugs for esophageal cancer, and broad-spectrum antibacterial anti-inflammatory drugs, As well as various drugs for diabetes and obesity, this company is a specialty. At that time, Amgen was counting on the acquisition of this company, relying on the company's technology, experience, and channels to make a great difference in the field of traditional medicine manufacturing... ”

Scott said this, Jin Muchen basically understood, it seems that the development has reached now, it should be Amgen, and the $1.3 billion thrown on this Duraric company has been lost, and now they are going to cut off their arms.

And Scott's next explanation also confirmed his guess.

"But Amgen would never have thought that their acquisition of Dularic at this time would touch the scales of those large pharmaceutical companies. You must know that if they continue to engage in special drugs for incurable diseases, or continue to engage in their biopharmaceuticals, those large pharmaceutical companies may not say anything, after all, the fields of specialization are different, and it is good that everyone's well water does not interfere with river water. But at this time, you are trying to enter the field of traditional pharmaceutical manufacturing, that is to cross the line, so the products of this Duraric company have been sniped by those large pharmaceutical companies, and have also hyped up the company's several phases of pharmaceutical failure, or the scandal of excessive drug power and death, this Duraric company is thin, they were acquired by Amgen Company for a year, because of several scandals, As a result, the company's stock price plummeted by $1.5 per share, and Amgen lost $151 million on the company that year, and in the following ten years, because of the strict defense of those large pharmaceutical companies, the development of the Duraric company can only be said to be worse. By now, the market value of their company has been seriously depreciated to the point that it is only 37% of what it was when Amgen bought them... (To be continued.) )